Cancer Immunology


Selected Publications

Burckhard T.,Thiel M.,Nishikawa H.,Wüest T.,Müller D., Zippelius A., Ritter G., Old L., Shiku H., Renner C. (2010) Tumor-specific crosslinking of GITR as costimulation for immunotherapy. J Immunotherapy 33, 925-934

Speiser D.E.,Schwarz K.,Baumgaertner P.,Manolova V., Devevre E., Sterry W., Walden P., Zippelius A., Conzett K.B., Senti G., Voelter V., Cerottini J.P., Guggisberg D., Willers J., Geldhof C., Romero P., Kündig T., Knuth A., Dummer R., Trefzer U., Bachmann M.F.(2010) Memory and effector CD8 T-cell responses after nanoparticle vac- cination of melanoma patients. J Immunother 33, 848-858

Wicki A.,Rochlitz C.,Orleth A.,Ritschard R.,Albrecht I., Herrmann R., Christofori G., Mamot C. (2012) Targeting tumor-associated endothelial cells: anti-VEGFR2 immuno- liposomes mediate tumor vessel disruption and inhibit tu- mor growth. Clin Cancer Res 18, 454-464

Mamot C.,Ritschard R.,Wicki A.,Stehle G.,Dieterle T., Bubendorf L., Hilker C., Deuster S., Herrmann R., Rochlitz C. (2012) Tolerability, safety, pharmacokinetics, and effica- cy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase I dose-escalation study. Lancet Oncol 13, 1234-1241

Stenner F., Liewen H., Göttig S., Henschler R., Markuly N., Kleber S., Faust M., Mischo A., Bauser S., Zweifel M., Knuth A., Renner C., Wadle A.(2013) RP1 is a phospho- rylation target of CK2 and is involved in cell adhesion. PLoS One 8, e67595

Müller P, Kreuzaler M, Khan T, Thommen DS, Martin K, Glatz K,Savic S, Harbeck N, Nitz U, Gluz O, von Bergwelt-Baildon M, Kreipe H, Reddy S, Christgen M, Zippelius A. Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible toCTLA-4/PD-1 blockade.Sci Transl Med. 2015 Nov 25;7(315):315ra188.

Müller P, Rothschild SI, Arnold W, Hirschmann P, Horvath L, Bubendorf L, Savic S, Zippelius A. Metastatic spread in patients with non-small cell lung cancer is associated with a reduced density of tumor-infiltrating T cells.Cancer Immunol Immunother. 2016 Jan;65(1):1-11.

Thommen DS, Schreiner J, Müller P, Herzig P, Roller A, Belousov A, Umana P, Pisa P, Klein C, Bacac M, Fischer OS, Moersig W, Savic Prince S, Levitsky V, Karanikas V, Lardinois D, Zippelius A. Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors. Cancer Immunol Res. 2015 Dec;3(12):1344-55.

Wieckowski S, Hemmerle T, Prince SS, Schlienger BD, Hillinger S, Neri D, Zippelius A. Therapeutic efficacy of the F8-IL2 immunocytokine in a metastatic mouse model of lung adenocarcinoma. Lung Cancer. 2015 Apr;88(1):9-15.

Zippelius A, Schreiner J, Herzig P, Müller P. Induced PD-L1 expression mediates acquired resistance to agonistic anti-CD40 treatment. Cancer Immunol Res. 2015 Mar;3(3):236-44.

Müller P, Martin K, Theurich S, Schreiner J, Savic S, Terszowski G, Lardinois D, Heinzelmann-Schwarz VA, Schlaak M, Kvasnicka HM, Spagnoli G, Dirnhofer S, Speiser DE, von Bergwelt-Baildon M, Zippelius A. Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells. Cancer Immunol Res. 2014 Aug;2(8):741-55.

Martin K, Müller P, Schreiner J, Prince SS, Lardinois D, Heinzelmann-Schwarz VA, Thommen DS, Zippelius A. The microtubule-depolymerizing agent ansamitocin P3 programs dendritic cells toward enhanced anti-tumor immunity. Cancer Immunol Immunother. 2014 Sep;63(9):925-38.